Svedbom, A., Dalén, J., Black, C. M., & Kachroo, S. (2017). Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. Patient Prefer Adherence.
Dyfyniad Arddull ChicagoSvedbom, Axel, Johan Dalén, Christopher M. Black, and Sumesh Kachroo. "Persistence and Costs With Subcutaneous TNF-alpha Inhibitors in Immune-mediated Rheumatic Disease Stratified By Treatment Line." Patient Prefer Adherence 2017.
Dyfyniad MLASvedbom, Axel, Johan Dalén, Christopher M. Black, and Sumesh Kachroo. "Persistence and Costs With Subcutaneous TNF-alpha Inhibitors in Immune-mediated Rheumatic Disease Stratified By Treatment Line." Patient Prefer Adherence 2017.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.